17 December 2021 - Recommendation based on results from the Phase 3 CROWN trial, which showed Lorviqua reduced the risk of cancer progression or death by 72% in newly diagnosed individuals compared to Xalkori (crizotinib).
Pfizer announced that the CHMP of the EMA has adopted a positive opinion recommending Lorviqua (lorlatinib, available in the U.S. under the brand name Lorbrena) for marketing authorisation as a first-line treatment of adults with anaplastic lymphoma kinase positive advanced non-small cell lung cancer.